Ergoteles’s MaxCyte MXCT Stock Holding History

Ergoteles’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-64,500	Closed	-$305K	–	1832
2022 Q2	$305K	Buy	+64,500	New	+$318K	0.01%	1094

Other funds holding MXCT

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BWLSA

Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

RGI

River Global Investors London, United Kingdom $515M AUM 24.86% 1-Year Est. Return

Ergoteles's MXCT Position: Q3 2022 in Review

Ergoteles sold out of MaxCyte (MXCT) in Q3 2022, closing a stake of 64,500 shares — an estimated $305K sold.

Ergoteles first reported a position in MXCT in Q2 2022 and held it in 1 quarter. The position peaked at $305K in Q2 2022. 108 funds tracked by Wall St. Rank hold MXCT as of Q3 2022.

Ergoteles reported no remaining MaxCyte position as of Q3 2022 after selling out during the quarter.
Ergoteles sold 64,500 MaxCyte shares in Q3 2022, an estimated $305K.
Ergoteles first reported a position in MaxCyte in Q2 2022 and held it in 1 quarter.
Ergoteles's MaxCyte position peaked at $305K in Q2 2022.
108 funds tracked by Wall St. Rank held MaxCyte as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.